Stockwatch: Natural History Confounds Surrogate Endpoints
This article was originally published in Scrip
Executive Summary
Like the NASDAQ Biotech Index, the stock price of BioMarin Pharmaceuticals Inc. finished the shortened trading week about where it started, although this masked a drop of about 3% for BioMarin on the day it announced the results of its PRISM-2 Phase III study of pegvaliase in patients with phenylketonuria (PKU).